Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,934 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Yonesaka K, Hayashi H, Nakamura A, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Ito K, Yano Y, Matsumoto H, Daga H, Hata A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Nakagawa K. Yonesaka K, et al. Among authors: sakai k. Clin Lung Cancer. 2023 Sep;24(6):519-527.e4. doi: 10.1016/j.cllc.2023.05.008. Epub 2023 Jun 3. Clin Lung Cancer. 2023. PMID: 37344331 Clinical Trial.
FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.
Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K, Nishio K. Kaneda H, et al. Among authors: sakai k. Cancer Res. 2010 Mar 1;70(5):2053-63. doi: 10.1158/0008-5472.CAN-09-2161. Epub 2010 Feb 9. Cancer Res. 2010. PMID: 20145154
Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N, Nishio K. Kasahara K, et al. Among authors: sakai a, sakai k. Clin Cancer Res. 2010 Sep 15;16(18):4616-24. doi: 10.1158/1078-0432.CCR-10-0383. Epub 2010 Aug 2. Clin Cancer Res. 2010. PMID: 20679350
Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.
Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, De Velasco MA, Fujita Y, Saijo N, Kudo M, Nishio K. Kudo K, et al. Among authors: sakai k. Clin Cancer Res. 2011 Mar 15;17(6):1373-81. doi: 10.1158/1078-0432.CCR-09-2755. Epub 2010 Dec 3. Clin Cancer Res. 2011. PMID: 21131553
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K. Azuma K, et al. Among authors: sakai k. Biochem Biophys Res Commun. 2011 Apr 1;407(1):219-24. doi: 10.1016/j.bbrc.2011.03.002. Epub 2011 Mar 4. Biochem Biophys Res Commun. 2011. PMID: 21377448
4,934 results